• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Envista Holdings Corporation

    5/1/24 4:22:12 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email
    DEFA14A 1 nvstproxysupplement-change.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No. )

    ☑ Filed by the Registrant☐ Filed by a party other than the Registrant

    CHECK THE APPROPRIATE BOX:
    ☐ Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☑ Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12


    envistalogo.jpg
    ENVISTA HOLDINGS CORPORATION
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)


    PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):
    ☑ No fee required
    ☐Fee paid previously with preliminary materials
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11





















    envistalogo.jpg
    May 1, 2024

    Dear Stockholders:

    As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2024, Envista Holdings Corporation (“Envista,” “we”, “us”, “our” or the “Company”) and Amir Aghdaei, the Company’s President and Chief Executive Officer, entered into a transition letter agreement (the “Transition Agreement”), setting forth the terms of Mr. Aghdaei’s anticipated transition from his position as the Company’s President and Chief Executive Officer. Pursuant to the terms of the Transition Agreement, effective upon the appointment of a successor Chief Executive Officer of the Company by the Company’s Board of Directors (the “Board”), Mr. Aghdaei’s employment with the Company and his membership on the Board will immediately cease. On April 15, 2024, we announced that our Board appointed Paul Keel as the President and Chief Executive Officer of the Company and as a director of the Company. These appointments are effective as of 5:00 pm PT on May 1, 2024. Mr. Keel’s term will expire at the 2024 Annual Meeting of Stockholders to be held on May 21, 2024 (the “Annual Meeting”).

    Accordingly, our Board has nominated Paul Keel for re-election to the Board at the Annual Meeting. Because this change adds Mr. Keel to the slate of director nominees proposed to be elected at the Annual Meeting, we are providing you with additional information in the enclosed Supplement to Proxy Statement and an amended proxy card to allow stockholders to vote on the election of Mr. Keel as a director. For technical purposes, the election of Mr. Keel as a director is being considered as a separate proposal (Proposal 5).

    You should resubmit your vote on all five proposals in your proxy or voting instructions by one of the alternatives described in the Supplement. The receipt of your new proxy or voting instructions will revoke and supersede any proxy or voting instructions previously submitted. If you have already voted and do not submit new voting instructions, your previously submitted proxy or voting instructions will be voted at the Annual Meeting with respect to all other proposals but will not be counted in determining the outcome of the election of Mr. Keel to our Board. Additionally, any votes cast for Mr. Aghdaei will be disregarded and will not be counted, as Mr. Aghdaei is no longer standing for re-election at the Annual Meeting.

    Please read the Proxy Statement that was previously made available to stockholders and the attached Supplement in their entirety, as together they contain all of the information that is important to your decisions in voting at the Annual Meeting.
    By Order of the Board of Directors,
    Mark Nance
    Secretary





    ENVISTA HOLDINGS CORPORATION
    200 S. Kraemer Boulevard, Building E
    Brea, CA 92821
    Amended Notice of 2024 Annual Meeting of Stockholders    
     
           
    ¶3?:
    When:
    May 21, 2024 at 7:30 a.m., PT.
    Where:
    Virtually, at www.virtualshareholdermeeting.com/NVST2024
     
    Items of Business:
    5 measures to review as listed below
     
    Who Can Vote:
    Stockholders of Envista’s common stock at the close of business on March 25, 2024.
     
    Attending the Meeting:
     Stockholders will be able to attend, vote and submit questions during the Annual Meeting from any location via the Internet.*
    Date of Mailing:
    We previously mailed the Proxy Statement or Notice of Internet Availability to our stockholders on or about April 8, 2024. The date of mailing of the Supplement to Proxy Statement is on or about May 1, 2024.
    *The 2024 Annual Meeting will be a virtual meeting conducted solely online and can be attended by visiting www.virtualshareholdermeeting.com/NVST2024.
    Items of Business:

    1. To elect the director nominees named in Proposal 1 in the Proxy Statement, other than Mr. Aghdaei, who has resigned from the Board effective May 1, 2024, each for a one-year term expiring at the 2025 annual meeting of stockholders and until their successors are elected and qualified.
    2. To ratify the selection of Ernst & Young LLP as Envista’s independent registered public accounting firm for the year ending December 31, 2024.
    3. To approve on an advisory basis Envista’s named executive officer compensation.
    4. To approve a proposal to amend our Second Amended and Restated Certificate of Incorporation to include an officer exculpation provision.
    5. To elect Paul Keel as a director for a one-year term expiring at the 2025 annual meeting of stockholders and until his successor is elected and qualified.
    6. To consider and act upon such other business as may properly come before the meeting or any adjournment thereof.

    YOUR VOTE IS IMPORTANT. PLEASE SUBMIT YOUR PROXY OR VOTING INSTRUCTIONS AT YOUR EARLIEST CONVENIENCE, WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING.




    Most stockholders have a choice of voting over the Internet, by telephone or by using a traditional proxy card or voting instruction form. Please refer to the attached proxy materials or the information forwarded by your bank, broker or other holder of record to see which voting methods are available to you.

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MAY 21, 2024:

    The Amended Notice of Annual Meeting, Proxy Statement, Supplement to Proxy Statement and the Annual Report are available at: http://www.proxyvote.com.
    By Order of the Board of Directors,
    Mark Nance
    Secretary
    May 1, 2024






    SUPPLEMENT TO PROXY STATEMENT
    FOR THE ANNUAL MEETING OF STOCKHOLDERS
    To Be Held May 21, 2024
    May 1, 2024
    This Supplement to Proxy Statement (this “Supplement”) is furnished to the stockholders of Envista Holdings Corporation (“Envista,” “we”, “us”, “our” or the “Company”) in connection with the solicitation of proxies for use at the Annual Meeting of Stockholders to be held on May 21, 2024 (the “Annual Meeting”), or at any adjournments or postponements thereof, pursuant to the accompanying Amended Notice of Annual Meeting of Stockholders. This Supplement and the Amended Notice of Annual Meeting of Stockholders supplement and amend the Notice of Annual Meeting of Stockholders and the Proxy Statement, each dated April 8, 2024.
    This Supplement is being furnished to provide information related to Proposal 5, which has been newly added to the agenda for the Annual Meeting. This Supplement does not provide all of the information that is important to your decisions in voting at the Annual Meeting. Additional information is contained in the Proxy Statement for our Annual Meeting that was previously sent to our stockholders.
    On April 8, 2024, the Company filed its proxy statement (the “Proxy Statement”) relating to the Annual Meeting with the Securities and Exchange Commission and began mailing the Proxy Statement or Notice of Internet Availability to its stockholders on or about April 8, 2024. Subsequent to that date, the Board of Directors of the Company (the “Board”) elected Paul Keel as a director, effective at 5:00 pm PT on May 1, 2024, filling the vacancy resulting from Amir Aghdaei’s resignation from the Board effective at such time. Mr. Keel’s term will expire on the date of the Annual Meeting and, accordingly, our Board has nominated Mr. Keel for re-election to the Board at the Annual Meeting. These additional materials have been prepared to provide the Company’s stockholders with information regarding the new nominee for director that would have been included in the Proxy Statement had the nominee been nominated prior to the filing of the Proxy Statement.
    Nomination of Director
    The Board elected Paul Keel as a director, effective as of 5:00 pm PT on May 1, 2024, filling the vacancy resulting from Amir Aghdaei’s resignation from the Board effective at such time. Mr. Keel’s term as a director will expire on the date of the Annual Meeting. Mr. Keel has been nominated for re-election as a director at the Annual Meeting to serve a one-year term expiring at the 2025 Annual Meeting of Stockholders and until his successor is elected and qualified. The Board has affirmatively determined that Mr. Keel will not be independent under the listing standards of the New York Stock Exchange given his role as our President and Chief Executive Officer.
    The amended proxy card enclosed with this Supplement differs from the proxy card previously furnished to you with the Proxy Statement dated April 8, 2024, in that the enclosed amended proxy card includes the additional Proposal 5. You should resubmit your vote on all five proposals by submitting the amended proxy card enclosed with this Supplement. If you have already voted and do not submit a new proxy card or new voting instructions, your previously submitted proxy or voting instructions will be voted at the Annual Meeting with respect to all other proposals but will not be counted in determining the outcome of the election of Mr. Keel to our Board, and any votes cast for Mr. Aghdaei will be disregarded and not counted.






    Proposal 5. Election of Additional Director

    The Board elected Paul Keel as a director, effective as of 5:00 pm PT on May 1, 2024, filling the vacancy resulting from Amir Aghdaei’s resignation from the Board effective at such time. Mr. Keel’s term will expire on the date of the Annual Meeting. Accordingly, the Board has nominated Mr. Keel for re-election as a director to serve a one-year term expiring at the Annual Meeting of Stockholders in 2025 and until his successor is duly elected and qualified. The Board has affirmatively determined that Mr. Keel will not be independent under the listing standards of the New York Stock Exchange given his role as our President and Chief Executive Officer.

    If elected at the Annual Meeting, Mr. Keel will serve a one-year term expiring at the Annual Meeting of Stockholders in 2025, and until his successor shall have been elected and qualified, subject to earlier death, resignation or removal. Mr. Keel has indicated a willingness to serve as director if elected. In the event Mr. Keel is unable to serve, the proxies may be voted in the discretion of the proxy holders for a substitute. Management has no reason to believe that Mr. Keel will be unable or unwilling to serve if elected.

    Business Experience of Mr. Keel

    Mr. Keel, age 54, served as Chief Executive Officer of Smiths Group plc, a global technology company and FTSE 100 constituent from May 2021 to March 2024. Prior to that, Mr. Keel served as Group President of 3M Company’s Consumer Business Group from March 2019 to August 2020. Mr. Keel joined 3M in 2004 and held various leadership roles including President of 3M Medical and President of 3M Unitek, a specialty dental business. Prior to joining 3M, Mr. Keel held positions of increasing responsibility at GE, McKinsey & Company, and General Mills.

    Mr. Keel’s qualifications to sit on the Board include, among other factors, his prior public company CEO experience and his extensive experience in senior leadership positions and operational experience in the medical and oral care markets.

    Stock Ownership of Mr. Keel
    Mr. Keel does not beneficially own any shares of the Company’s common stock as of the date of this Supplement.

    THE BOARD OF DIRECTORS RECOMMENDS YOU VOTE FOR MR. KEEL. A PROPERLY SUBMITTED AMENDED PROXY CARD WILL BE SO VOTED UNLESS THE STOCKHOLDER SPECIFIES OTHERWISE.

    Required Vote

    With regard to the election of the nominee for director named in Proposal 5, you may vote “FOR” the nominee or “WITHHOLD” your vote for the nominee. The Company’s Bylaws provide for the election of directors by a plurality of the votes cast by the shares entitled to vote, provided that a quorum is present. A “plurality of the votes cast” means that the individuals with the highest number of votes are elected as directors up to the maximum number of directors to be elected.
    Withhold votes are not considered votes cast for the foregoing purpose. If you withhold your vote on the election of this nominee to our Board, it will have no effect on the outcome of the vote on Proposal 5. Abstentions and broker non-votes are counted as present for purposes of determining a quorum but will have no effect on the outcome of the vote on Proposal 5.




    VOTING; REVOCABILITY OF PROXIES

    If you sign and return the amended proxy card, or vote by Internet or telephone on the proposals included in the amended proxy card, it will revoke and replace any previous proxy you have submitted. If you do not sign and return the amended proxy card, or vote by Internet or telephone on the proposals included in the amended proxy card, your previous proxy will remain in effect, but it will not include any vote on Mr. Keel as a nominee for director (as Mr. Aghdaei is no longer standing for re-election), and any votes cast for Mr. Aghdaei will be disregarded and will not be counted. In order to vote on Mr. Keel as a nominee for director you must submit a vote on Proposal 5 via the Internet, telephone or by completing, signing, dating and returning the enclosed amended proxy card in the envelope provided, or by attending the virtual Annual Meeting and voting your shares at the meeting. Telephone and Internet voting for registered stockholders will be available 24 hours a day, up until 11:59 p.m., Eastern time on May 20, 2024.

    If you hold the Company’s common stock in “street name,” you must either instruct your bank, broker or other nominee as to how to vote such shares or obtain a proxy, executed in your favor by your bank, broker or other nominee, to be able to vote at the Annual Meeting.

    If the amended proxy card or original proxy card is properly signed, dated and returned and is not revoked, the proxy will be voted at the Annual Meeting in accordance with the stockholder’s instructions indicated on the most recently dated proxy.

    If no instructions are indicated on the amended proxy card, your shares will be voted:

    ▪    FOR the election of each of the director nominees identified in Proposal 1 in the Proxy Statement, other than Mr. Aghdaei, to serve as directors, each for a one-year term expiring at the 2025 Annual Meeting;
    ▪    FOR ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024;

    ▪    FOR approval of our named executive officer compensation;

    ▪    FOR approval of an Amendment to our Second Amended and Restated Certificate of Incorporation to include an officer exculpation provision;

    ▪    FOR Mr. Keel as a director; and

    ▪    in the discretion of the proxy holders on any other matter that properly comes before the meeting or any adjournment thereof. 

    Any person giving a proxy pursuant to this solicitation has the power to revoke it at any time before it is voted. It may be revoked by filing with the Secretary of Envista a written notice of revocation or a duly executed proxy bearing a later date, or it may be revoked by virtually attending the meeting and voting in person. Please note, however, that if your shares are held of record by a broker, bank or nominee and you wish to revoke your proxy or vote at the meeting, you must follow the instructions provided to you by the record holder and/or obtain from the record holder a proxy issued in your name. Virtual attendance at the meeting will not, by itself, revoke a proxy. 

    OTHER MATTERS COMING BEFORE THE MEETING

    As of the date of this Supplement, the Board of Directors does not know of any matters to be presented to the Annual Meeting other than the matters set forth in the accompanying Amended Notice of Annual Meeting of Stockholders. If any other matter properly comes before the Annual Meeting, it is intended that the holders of the proxies will vote thereon in their discretion.




    ballot2pg1screenshot2024-0.jpg







    ballot2pg2screenshot2024-0.jpg


    Get the next $NVST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    2/6/2026$35.00Market Perform → Outperform
    Leerink Partners
    12/9/2025$24.00Overweight
    Barclays
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $NVST
    SEC Filings

    View All

    SEC Form S-8 POS filed by Envista Holdings Corporation

    S-8 POS - Envista Holdings Corp (0001757073) (Filer)

    2/18/26 4:25:33 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Envista Holdings Corporation

    S-8 POS - Envista Holdings Corp (0001757073) (Filer)

    2/18/26 4:23:26 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Envista Holdings Corporation

    10-K - Envista Holdings Corp (0001757073) (Filer)

    2/12/26 4:18:39 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envista Reports Fourth Quarter 2025 Results

    BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2025. "With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista," said Paul Keel, CEO.  "We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025.  In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee d

    2/5/26 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Fourth Quarter 2025 Earnings Call

    BREA, Calif., Jan. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2025 on Thursday, February 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y

    1/8/26 4:20:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BREA, Calif., Jan. 7, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 12, 2026, from 3:45 – 4:25 pm PST.  A live audio webcast of the event will be available in the Investors section of the Envista website at https://investors.envistaco.com/. Additionally, a replay of the webcast will be available on the Envista website for 30 days following the presentation. ABOUT ENVISTA HOLDINGS CORPORATION Envista

    1/7/26 4:15:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Strategy & Bus. Dev. Reis Mischa exercised 9,675 shares at a strike of $17.25 and sold $290,250 worth of shares (9,675 units at $30.00) (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    2/11/26 5:15:57 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Keel Paul A

    4 - Envista Holdings Corp (0001757073) (Issuer)

    2/3/26 9:04:09 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Hammes Eric D.

    4 - Envista Holdings Corp (0001757073) (Issuer)

    2/3/26 9:04:15 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Market Perform to Outperform and set a new price target of $35.00

    2/6/26 8:05:48 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Envista with a new price target

    Barclays initiated coverage of Envista with a rating of Overweight and set a new price target of $24.00

    12/9/25 8:46:01 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

    5/27/25 9:05:49 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/14/24 4:40:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/13/24 6:01:10 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    11/20/23 5:49:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Financials

    Live finance-specific insights

    View All

    Envista Reports Fourth Quarter 2025 Results

    BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2025. "With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista," said Paul Keel, CEO.  "We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025.  In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee d

    2/5/26 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Fourth Quarter 2025 Earnings Call

    BREA, Calif., Jan. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2025 on Thursday, February 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y

    1/8/26 4:20:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Reports Third Quarter 2025 Results

    BREA, Calif., Oct. 29, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended September 26, 2025. This was another strong quarter for Envista"This was another strong quarter for Envista, with core growth, adjusted EBITDA, and adjusted EPS all ahead of expectations," said Paul Keel, CEO. "We delivered positive growth in all major businesses and once again captured share with Spark aligners, while also turning to profitability in the business. My thanks to our teams around the world for making all this progress possible." Fina

    10/29/25 8:28:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Compass Diversified Announces Stephen Keller as Chief Financial Officer

    WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

    8/26/24 6:00:00 AM ET
    $AVY
    $CODI
    $NVST
    Containers/Packaging
    Consumer Discretionary
    Home Furnishings
    Medical/Dental Instruments

    Envista Holdings Corporation Announces Key Leadership Appointments

    BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

    7/15/24 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    11/8/24 12:09:03 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    2/14/24 4:08:38 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care